• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Exploring Rebyota for Recurrent C Difficile Infections

Opinion
Video

The panelist discusses how Rebyota is an FDA-approved microbiome therapeutic that delivers standardized, purified intestinal microbiota through enema administration to restore gut microbial diversity and prevent recurrent Clostridioides difficile infection, differing from conventional fecal microbiota transplantation (FMT) in its regulatory status, standardized manufacturing process, and enhanced safety profile due to extensive screening and purification of donor material.

Related Videos
1 expert is featured in this series.
5 experts are featured in this series.
5 experts are featured in this series
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.